GlassScriptPhysician profile
Robert W Regenhardt
NPI 1770900128
$4,832.01
in general payments reported to CMS, 2019-2025
12 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $153 · 2021: $538 · 2022: $1,715 · 2023: $796 · 2024: $657 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.82 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $1,337.35 | 2021-2025 | Stent, Web Aneurysm Embolization System, Hydrosoft Advanced |
| Stryker Corporation | $1,310.22 | 2021-2025 | Surpass Evolve, Broadway 8, Target |
| Medtronic, INC. | $480.42 | 2021-2024 | Axium Primetm, Pipeline |
| Route 92 Medical, INC. | $424.78 | 2023-2025 | 8f Base Camp Sheath System |
| Rapid Medical LTD | $384.28 | 2022 | |
| Penumbra, INC. | $252.86 | 2020-2022 | |
| Vesalio, INC. | $250.00 | 2025 | |
| Depuy Synthes Sales INC. | $134.90 | 2025 | Embotrap, Emboguard |
| Qapel Medical INC | $127.04 | 2023 | |
| Medical Device Business Services, INC. | $87.21 | 2022 | |
| Acadia Pharmaceuticals INC | $24.94 | 2025 | Nuplazid |
| Abbvie INC. | $18.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Regenhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.